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Telomere) is a multi-system disorder which in its classical form is characterised by
abnormalities of the skin, nails and mucous membranes. In approximately 80% of cases, it is associated with
bone marrow dysfunction. A variety of other abnormalities (including bone, brain, cancer, dental, eye,
gastrointestinal, immunological and lung) have also been reported. Although ﬁrst described almost a century
ago it is the last 10 years, following the identiﬁcation of the ﬁrst DC gene (DKC1) in 1998, in which there has
been rapid progress in its understanding. Six genes have been identiﬁed, defects in which cause different
genetic subtypes (X-linked recessive, autosomal dominant, autosomal recessive) of DC. The products of these
genes encode components that are critical for telomere maintenance; either because they are core
constituents of telomerase (dyskerin, TERC, TERT, NOP10 and NHP2) or are part of the shelterin complex that
protects the telomeric end (TIN2). These advances have also highlighted the connection between the more
“cryptic/atypical” forms of the disease including aplastic anaemia and idiopathic pulmonary ﬁbrosis. Equally,
studies on this disease have demonstrated the critical importance of telomeres in human cells (including
stem cells) and the severe consequences of their dysfunction. In this context DC and related diseases can now
be regarded as disorders of “telomere and stem cell dysfunction”.
© 2009 Elsevier B.V. Open access under CC BY license.1. Dyskeratosis congenitaFirst described as a discrete syndrome in 1910 [1], dyskeratosis
congenita (DC) is a disease that can be pigeon-holed into a number of
alternative classiﬁcations including “premature aging syndrome”,
“bone marrow failure syndrome” and “cancer predisposition syn-
drome”, amongst others. In truth, DC is a highly heterogeneous
disorder that is difﬁcult to classify with precision. It was initially
described as a mucocutaneous disorder and is still deﬁned today
largely by the presence of nail dystrophy, oral leukoplakia and
abnormal skin pigmentation. The incidence of bone marrow failure
is so high that this too is now considered a deﬁning feature and the
deﬁnition is continually expanding as links with other clinical and
molecular features become more ﬁrmly established.
As well as presenting with a broad spectrum of clinical features,
mutations in many genes are known to be causative (six have been
published so far) with X-linked, autosomal recessive and autosomal
dominant modes of inheritance recognised alongside sporadic cases
[2]. Because of this clinical and genetic heterogeneity, multiple
mechanisms have been postulated by which the abnormalities of DC
might arise. However, the disease as it manifests in humans is widely
considered to be due to defects in telomerase or in telomeretitute of Cell and Molecular
ntistry, QueenMary University
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 license.maintenance. This is due at least in part to the nature of the affected
genes – DKC1, TERC, TERT, NOP10, NHP2 and TINF2 – all of which are
somehow implicated in telomere function. The severe implications of
defects in the telomeric system in DC demonstrate the importance for
telomere function in normal human health and this makes DC an
excellentmodel for studying both the normal and abnormal behaviour
of telomere biology in humans.
1.1. Clinical presentation
As alreadymentioned nail dystrophy, oral leukoplakia and abnormal
skin pigmentation are deﬁning features of DC and have been referred to
as the classical or common mucocutaneous triad (Fig. 1) as they are
present in around 80–90% of diagnosed cases. Bone marrow failure is
the other common feature that will develop in around 85% of cases and
is responsible for 80% of the observed mortality [3] (Fig. 2). However,
there is a plethora of other disease manifestations ranging from
epiphora (excessive tears in the eyes), mental retardation, pulmonary
disease (including pulmonary ﬁbrosis and abnormal pulmonary
vasculature), dental loss/caries and premature hair loss/greying to
liver disease, osteoporosis and deafness [4]. Features often present in
early life with skin pigmentation and nail changes usually appearing by
10 years of age followed later by mucosal leukoplakia and bonemarrow
failure. Epithelial tumours often begin to develop by the mid-teens and
commonly arise in the gastrointestinal tract or in areas of mucosa with
leukoplakia [2, 5–7]. Many of the other features such as premature loss
or greying of the hair and osteoporosis are more commonly seen with
Fig. 1. Clinical features of dyskeratosis congenita. The three mucocutaneous features that classically characterise dyskeratosis congenita are shown: (A) abnormal skin pigmentation;
(B) nail dystrophy; (C) oral leukoplakia.
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causative factor [8]. The clinical phenotype of DC is continually
expanding and so, in an effort to rationalise the diagnosis, a deﬁnition
has tentatively been decided upon that is one or more of the classical
mucocutaneous features combined with a hypoplastic (incompletely
developed or hypocellular) bone marrow and at least two of the other
somatic features [9].
One common non-clinical feature of DC is the presence of
abnormally short telomeres [9,10] which is suspected as being the
common, underlying cause behind most of the abnormalities.
Inherited forms of the disease also demonstrate the phenomenon of
anticipation [11–13] whereby successive generations of an affected
family present with progressively more severe disease features and at
an earlier age. This is probably due to the inheritance of short
telomeres from the parent whichmay then also continue to shorten at
an accelerated pace due to the inherited disease-causing mutation.
Several other diseases overlap with DC to the extent that they
could be considered DC variants and all with the same genetic lesions.
Mutations in DKC1 and homozygous mutations in TERT have been
shown to cause Hoyeraal–Hreidarsson syndrome (HH) [14,15], a
severe multi-system disorder characterised by severe growth retarda-
tion, bone marrow failure, immunodeﬁciency and cerebellar hypo-
plasia [16–19]. Heterozygous TERC and TERT mutations have been
implicated in around 5–10% of cases of aplastic anaemia (AA) [20–22],
another disease of defective bone marrow deﬁned as pancytopenia (aFig. 2.Histopathological features of dyskeratosis congenita (DC): (A) bonemarrow slides sho
grown from a patient with X-linked dyskeratosis congenita show a marked dysmorphism creduction in blood cells of all lineages) with a hypocellular marrow
[23]. Heterozygous TERC and TERT mutations have also been
implicated in cases of idiopathic pulmonary ﬁbrosis (IPF) [24, 25], a
chronic progressive lung disease with irreversible ﬁbrosis leading to
respiratory failure in most cases within 5 years [26].
1.2. Genetic basis of the disease
At the genetic level, DC is almost as heterogeneous as it is in its
clinical presentation. Mutations directly implicated as causing DC
have been identiﬁed in the genes DKC1, TERC, TERT, NOP10, NHP2 and
TINF2. The ﬁrst ﬁve of these genes all encode components of the
telomerase holoenzyme while TINF2 encodes a component of the
telomere shelterin complex (Fig. 3).
Mutations in DKC1 cause the X-linked form of DC [27]. This gene
encodes the nucleolar protein dyskerin which has a dual role as a
pseudouridine synthase via its TruB domain, homologous to that of
pseudouridine synthases in bacterial TruB proteins, yeast Pus4p and
the yeast dyskerin homologue Cb5fp [28], and as an RNA-binding
protein via its PUA domainwhich is predicted to play a role in binding
H/ACA and telomerase RNAs [29,30]. In humans, functional analyses
have revealed multiple roles for dyskerin, including ribosomal (r)RNA
processing, ribosomal subunit assembly and centromere and micro-
tubule binding [31–33]. Most disease-causing mutations found in
human dyskerin are clustered around the PUAdomain [30], suggestingw the loss of cells in an aplastic marrow, typical of dyskeratosis congenita; (B) ﬁbroblasts
ompared to those from a healthy individual.
Fig. 3. The telomerase and shelterin complexes. TERT, TERC, dyskerin, NOP10 and NHP2 in the telomerase complex and TIN2 in the shelterin complex have been shown to be mutated
in cases of dyskeratosis congenita. Only around 50% of cases have been characterised at the molecular level and the other molecules shown (as well as other, unknown molecules)
may yet prove to be implicated in the disease. Image derived from data in the telomerase database [93] and Cristofari et al. [94].
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DC patients also show reduced telomerase activity and reduced TERC
accumulation [34,35].
TERC is the 451 nucleotide RNA component of telomerase that acts
as a template for the addition of TTAGGG repeats that are added to
chromosome ends to form telomeres. Mutations in TERC are a major
cause of AD–DC [36]. Most of the TERC mutations identiﬁed are
located in the pseudoknot domain which contains the RNA template;
although large 5′ and 3′ end deletions and several other point
mutations have been identiﬁed. The resulting clinical phenotype can
vary from AA to DC, myelodysplasia or paroxysmal nocturnal
haemoglobinuria [9,20,24,37–41].
Telomerase reverse transcriptase (TERT) is the enzymatic compo-
nent of telomerase responsible for transcribing the TERC template into
the TTAGGG repeat at telomere ends. TERT mutation has been
implicated in AD-DC [12,13], AR-DC [15], HH [15], AA [21,22] and IPF
[25] and while many mutations have severe effects on enzyme
activity, in some cases the reduction is relatively mild, the mutation is
intronic and/or the allele does not always segregate fully with the
disease. For this reason, some TERT mutations can be considered as
“risk factors” rather than directly disease-causing.
Several other proteins also associate with TERT, TERC and dyskerin
in vivo, including the small nucleolar proteins NOP10, NHP2 and to a
lesser extent GAR1 [42]. Biallelic mutations in both NOP10 and NHP2
have been implicated in AR-DC, albeit in very rare instances and, like
dyskerin mutations, have been linked with reduced TERC levels in DC
patients [43,44].
While all these molecules are part of the telomerase complex,
dyskerin, NOP10, NHP2 and GAR1 are also integral components of the
H/ACA class of small nucleolar ribonucleoprotein particles (snoRNPs)
that bind small nucleolar RNAs (snoRNAs) [45]. These H/ACA snoRNPs
guide the site-directed pseudouridylation of target RNAs and process
ribosomal RNA and so are essential for ribosome biogenesis, pre-
mRNA splicing and translation as well as telomere maintenance. As
already mentioned, dyskerin is a pseudouridine synthase while
NOP10, NHP2 and GAR1 are necessary for maintaining the stability
of the H/ACA RNP complex and for pre-rRNA processing and cells
lacking these proteins are defective in pre-rRNA pseudouridylation
[46–48]. This, coupled with data from early animal models (see
below) has led to the hypothesis that defects in dyskerin lead to DC via
a pathway of aberrant ribosomal biogenesis and function, rather than
via a telomerase defect [27, 49]. However, evidence from studies of DC
in humans as well as in vitro studies on human cells, strongly
implicates telomerase and telomeres in the fundamental processesleading to DC and there is considerable evidence showing normal
functioning of pseudouridylation and rRNA precursor processing in
human cells with DKC1 mutations [35,50].
GAR1, like dyskerin, NOP10 and NHP2 is essential for pseudour-
idylation and ribosome biogenesis [48]. However, while GAR1 does
associate with telomerase in vivo it does not appear to co-purify from
human cells with the assembled telomerase complex [42], and knock-
down studies of this molecule suggest that its absence has no
discernable effect on TERC accumulation [44], suggesting that its
association is not required for catalytic activity. It is worth noting that,
at the time of writing, no DC-causing mutations have yet been
identiﬁed in the GAR1 gene despite over 100 index cases having been
screened in our lab alone, further hinting that DC is primarily a disease
of defective telomere biology.
TINF2 is the only gene so far implicated in DC that does not directly
involve the telomerase complex. It codes for the protein TIN2, a
component (along with the proteins TRF1, TRF2, Rap1, TPP1, and
POT1) of the telomere shelterin complex that protects telomere ends
[51]. TINF2 mutations cause AD-DC [52] in around 11% of all cases of
DC and in some cases HH [53]. While TINF2 is the ﬁrst DC-causing
gene identiﬁed outside of the telomerase complex, it is still essential
for telomere maintenance. While other forms of DC are thought to
cause increased telomere attrition through a reduction in TERC levels
or reduced enzymatic activity, TIN2 mutations are thought to lead to
more direct degradation of the telomere either by leaving the
telomere end open to non-speciﬁc degradation or by preventing it
from “opening-up” for telomerase to bind, although the mechanism
has yet to be fully elucidated. Although there are some exceptions,
patients with TINF2mutations tend to have very short telomeres — in
fact their telomeres are generally much shorter at a much earlier age
than patients with DC caused by any of the other known genes.
Furthermore, almost all known cases of TINF2-related DC are de novo,
suggesting that this form of DC is far more severe with presentation in
the ﬁrst few years of life in the ﬁrst generation. The de novo
presentation also hints that abnormally rapid telomere loss within
these patients is responsible for the disease, rather than the
inheritance of short telomeres from an asymptomatic parent.
2. Dysfunction of telomerase and telomere maintenance
2.1. Early animal models suggested a ribosomal defect
Data from early animal models of X-linked DC initially suggested a
ribosomal defect in the disease. The ﬁrst mouse model created was
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four-fold reduction of Dkc1mRNA expression in males and two-fold in
females [54]. Despite having telomeres of a normal length, within the
ﬁrst generation it exhibited several of the features of DC as seen in
humans including dyskeratosis of the skin, mild anaemia and a
propensity to develop tumours — albeit, with a much greater
incidence (50%) and different organ proﬁle to humans (e.g. mammary
glands and kidneys). Mouse Terc levels and telomerase activity were
reduced and telomeres did shorten in successive generations, but long
after the appearance of disease features. There was, however, clear
evidence of reduced pseudouridine levels and slower rRNA proces-
sing. Deletion of Dkc1 has been shown to be embryonically lethal if
induced during early embryogenesis [55]. Dkc1− hemizygous males
are non-viable and though female Dkc1+/− carriers are viable they are
unable to pass on the deleted gene. Mice completely lacking
telomerase activity have been generated and are viable in the ﬁrst
few generations [56,57]; therefore a telomerase defect is unlikely to
result in this loss of viability. Two DKC1 mutations found in humans
(Ala353Val and Gly402Glu), when introduced into mouse embryonic
stem cells, caused a defect in overall pseudouridylation, a decrease in
the rate of pre-rRNA processing and a decreased accumulation of
several H/ACA snoRNAs [58]. The Ala353Val mutation however, did
lead to severe destabilisation of TERC, a reduction in telomerase
activity, and a continuous shortening of telomeres with increasing
numbers of cell divisions in culture.
Models in other species also implicate telomere-independent
dysfunction associated with dyskerin: partial loss-of-function muta-
tions in the Drosophila DKC1 homologue gene mﬂ result in reduced
body size, developmental delay, reduced female fertility and mor-
phological abnormalities in the ovaries characteristic of apoptosis
[59]. In Drosophila, telomeres are not maintained by telomerase but by
a transposon-mediatedmechanism [60] and so these defects are likely
to be due to some telomere-independent function of mﬂ. Loss of
global pseudouridylation due to mutations in the yeast DKC1
homologue gene Cbf5p results in a slow-growth phenotype and,
although the cells remain viable at 25 °C, they display severe growth
defects [61].
2.2. Recent mouse models implicate telomerase and telomeres
Despite early animal models implicating the non-telomeric role of
DKC1 mutations in disease, a more recent mouse model that directly
disturbs telomere maintenance displays many of the features of DC,
directly implicating telomerase and telomere maintenance in devel-
opment of the phenotype. Mice null for the shelterin component
POT1bwere created that were smaller and had a reduced bodyweight,
became prematurely infertile, had increased apoptosis in cells of
the small intestine, hyperpigmentation of the paws, snout, ears, and
tail and around 25% developed nail abnormalities. When crossed
with mice deﬁcient for the mouse TERC homologue mTR, POT1b−/−
mTR+/− mice were generated that showed a signiﬁcant reduction
of telomere length, developed a severe and progressive bone
marrow failure and died at around 4–5 months of age [62].
Evidence from another mouse model shows that cells with a Dkc1
mutation observed in human cases of DC suffer a growth disadvan-
tage that may be due to activation of a DNA damage response that,
while acting via telomerase, is independent of telomere length [63].
Female mice, like humans and other mammals, undergo a process of
inactivation of half their X-chromosomes in early life which is
normally random [64–67]. In this study, female mice with exon 15
deleted from Dkc1 (Dkc1Δ15) showed a skewed X-inactivation pattern
for haematopoietic cells expressing the mutant allele, something
already observed in female DC patients [68]. In spleen cells of 3 week
old mice, normal and mutant dyskerin proteins were present in
roughly equal proportions, but by 22 weeks the mutant dyskerin
represented only 16% of the total pool, suggesting a growthdisadvantage for the cells expressing the mutant protein. When
Dkc1Δ15/+ females were crossed with Terc−/− or Tert−/− mice, this
skewing was not apparent in the telomerase negative progeny,
suggesting that the mechanism is telomerase-dependent. However,
since this was observed in mice in the ﬁrst generation before their
telomeres became unduly shortened, it appears to be independent of
telomere length. Treatment with etoposide, a topoisomerase inhi-
bitor that induces double-stranded breaks in DNA, revealed a
markedly increased response to DNA damage in mutant cells with
an increased localisation of DNA damage foci at the telomeres. The
increased response to DNA damage would presumably lead to an
increase in cell-cycle arrest and apoptosis. This telomere length-
independent mechanism could thus explain the presence of DC-like
features in the early mouse model within the context of normal
length telomeres.
Ultimately, regardless of the data in animal models, there is a
wealth of data from human study implicating telomerase and
telomeres in DC and all the genes seen to be mutated in cases of DC
are, without exception, directly implicated in telomere biology.
2.3. Telomerase mutations and DC
The molecular mechanism of TERC mutations appears to be either
to reduce RNA accumulation/stability or cause a telomerase catalytic
defect. TERC and TERT mutations have both been shown to adversely
impact telomerase enzymatic function through in vitro assays such as
the telomerase repeat ampliﬁcation protocol [69] and in vitro studies
reconstituting telomerase activity with a mix of wild type and mutant
TERC suggest that heterozygous mutations can cause disease though
haplo-insufﬁciency [70]. As yet, themechanism bywhichmutations in
DKC1, NOP10 and NHP2 affect telomerase has yet to be directly
elucidated — hence the continuing debate over the role of ribosome
biogenesis in disease. However, some evidence does indirectly
implicate telomerase. For example, in cases of DKC1, NOP10 and
NHP2mutation, there is a marked decrease in the steady-state level of
TERC within the cell [34,43,44,71], suggesting destabilisation of the
telomerase complex. Short telomeres are also a universal feature of DC
patients including those not associated with TERC or TERT mutations
[9,10,34,72]. In fact, critically short telomere length in lymphocytes
has been shown to be diagnostically discriminative for DC in around
90% of cases in one study [10].
That DKC1mutant cells might be subject to early cell cycle arrest is
supported by evidence of an increase in apoptosis in such cells, rather
than a proliferative defect. This is apparent in B lymphocyte cell lines
which can be cultured over many population doublings. Compared to
lines from unaffected individuals, there is a sharp increase in the
apoptotic fraction of cells carrying a dyskerin Tyr66Ala mutation as
the number of population doublings increases [50].
2.4. Telomere shelterin complex mutations
The ﬁnding of TINF2 mutations in DC is perhaps one of the most
critical in conﬁrming the role of telomeres in the disease. In
telomerase positive cells such as the HeLa tumour cell line, siRNA-
mediated knock-down of TIN2 or deletion of signiﬁcant portions of the
N-terminus of the protein leads to an increase in telomere length
[73,74]. This is because TIN2 appears to up-regulate the effect of the
poly (ADP-ribose) polymerase (PARP) tankyrase 1 (also known as
TIN1) by stabilising the formation of a TIN2–tankyrase 1–TRF1
complex. This in turn prevents binding of TRF1 to the telomere end.
Normally, when TRF1 binds to the telomere it recruits another protein,
POT1, and this complex blocks access to telomerase, so by preventing
TRF1 binding the telomere is left open for enzymatic extension. In the
case of amino acid mutations in TIN2 they might act by the same
mechanism as a knock-down and leave telomere ends permanently
unprotected in telomerase negative somatic tissues and thereby
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prevent the TIN2–tankyrase–TRF1 interaction, leaving TRF1 to fully
bind to the telomere and prevent any telomere-lengthening activity
during the period of rapid cell growth in embryogenesis and early life.
Obviously, the close interaction of the shelterin components necessary
for correct control of telomere maintenance suggests that shelterin
molecules other than TIN2 may well be implicated in some of the
approximately 50% of uncharacterised cases of DC.3. The stem cell defect
Having established that the likely primary cause of DC is a defect
in telomerase or telomere maintenance, how does this translate into
disease? In embryonic, foetal and early childhood development, all
tissues experience a high proliferative demand. In the context of
impaired telomere maintenance, this could lead to exaggerated
telomere attrition, in excess of that to be expected in healthy
individuals. Telomeres would be expected to shorten in telomerase
negative tissues throughout subsequent life at the normal rate but,
having been severely shortened earlier on, would reach critically
short lengths much earlier than normal. This would explain the
features of premature aging as tissues senesce or apoptose prema-
turely. In highly proliferative tissues, this effect would be greatly
exaggerated and these tissues would be expected to show the most
severe disorders, hence the prevalence of pathologies in the bone
marrow, gut and skin. Telomerase is not active in most somatic tissues
and therefore a disease of defective telomerase would be expected to
have its “ground zero” in a cell that would normally be telomerase
positive. This leaves only a few cell types including male germ line
cells, activated lymphocytes and stem cells [75]. Of these, the cell type
that is likely to give rise to defects in multiple organs is the stem cell
and since bone marrow failure is the cause of most DC-related
mortality it is the haematopoietic stem cell (HSC) that has received
the most research attention with defects having been identiﬁed in
several studies. From the point of view of treatment, an important
question is whether the defect is quantitative or qualitative, or a
mixture of both.Fig. 4. The defects in cellular proliferation and differentiation that give rise to dyskeratosis co
the embryonic stem cell and continuing through to adult cells. This in turn drives excessive t
takes the haematopoietic system as an example but the principles apply equally to other ti3.1. Defective haematopoiesis
Even in healthy individuals, HSC telomeres progressively shorten
with age [76] so increasing this rate of attrition is likely to severely
impair the HSC pool, eventually resulting in bone marrow failure
(Fig. 4). Studies of haematopoietic progenitors in DC show a clear
reduction in numbers in both the bone marrow and peripheral blood
[77–79] and in vitro studies of long term bone marrow culture
demonstrate a quantitative deﬁcit in global haematopoiesis [79].
Serial re-plating of DC progenitor colony forming units showed a
replicative defect with the number of new colonies rapidly declining
with serial passage [80]. Thus, early conclusions were of both
qualitative and quantitative defects in haematopoiesis. The bone
marrow CD34+ population is severely reduced in cases of aplastic
anaemia [81] and in at least one family with a TERC-derived AD–DC
[82] and these cells have abnormally short telomeres. However,
although the number of corresponding early haematopoietic pro-
genitors was reduced in AD-DC, their frequency within the CD34+
population was similar to wild type, the implication being that DC
stem cells are able to develop and differentiate normally but that
their replicative potential is reduced. Telomerase clearly plays a
critical role in extending the replicative potential of HSCs. Those
derived from mTR−/− mice when serially transplanted showed twice
the rate of telomere attrition and could be transplanted for only half
as many rounds as those from mTR+/+ mice [83]. It was therefore
hypothesised that replicative exhaustion of the HSC population is at
the heart of the haematopoietic defect in DC. It should be noted that
these studies have not yet been repeated in DC arising from the other
genetic backgrounds and therefore may not apply to all genetic
subtypes, where qualitative defects in haematopoiesis may exist.
If the previously mentioned study on Dkc1Δ15 mice is anything to
go by, it might be the case that DKC1 mutations cause impairment of
the HSC compartment even before telomeres become critically short.
If DKC1 mutation leads to an exaggerated response to DNA damage
and premature cell death then the HSC of a DC patient with a DKC1
mutationwould suffer a growth and survival disadvantage that would
likely result in qualitative impairment of differentiation and develop-
ment, as well as a quantitative reduction of the HSC pool.ngenita. Stem cell replication is impaired and cell survival is compromised starting with
issue-speciﬁc stem cell division, ultimately exhausting the stem cell reserve. This ﬁgure
ssues.
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poietic stem cells, telomerase dysfunction in BM stroma has an
extrinsic effect on HSCs, inhibiting HSC and progenitor function and
replication [84]. Telomerase deﬁcient mTR−/−mice showed impaired
B-lymphocyte development with reduction of cell proliferation and
increased apoptosis while myelopoiesis (development of new blood
cells in the marrow) was accelerated. This occurred with both
endogenous mTR−/− cells and cells transplanted from a wild type
mTR+/+ mouse, suggesting that the defective maturation was due to
the stromal environment rather than or in addition to the intrinsic
telomerase defect in the HSC. Engraftment of wild type BM cells into
an mTR−/− stromal background was also impaired in aged mice. All
of this raises the possibility that transplantation and genetic therapies
to correct DC defects in the HSC pool might have to overcome the
additional hurdle of a detrimental environment in the marrow.
However, this does not appear to be a universal feature of DC, as a
previous in vitro study using stroma derived frompatientswith AR-DC
andX-linkedDC to culturewild typeCD34+ cells showednormal levels
of haematopoiesis [79]. Once again, these differences may be due to
the differing genetic backgrounds that can give rise toDC andhighlight
the potential difﬁculty in developing a single treatment for such a
genetically heterogeneous disorder. The possibility that a DC patient's
stroma may be impaired in its ability to support HSC development
also implies difﬁculties in using HSC transplantation as a treatment for
the disease. Indeed, while allogeneic bone marrow transplantation
can be successful in treating the pancytopenia in DC, fatal complica-
tions after transplantation are particularly common [85,86]. However,
whether this is due to HSC engraftment or the systemic defects
present in DC patients has not been conclusively demonstrated.
3.2. Non-haematological abnormalities
While the stem cell is at the heart of the disease, and certainly
responsible for the bone marrow failure seen in DC, some of the non-
haematological features and those of premature aging might also beFig. 5. A model of dyskeratosis congenita pathology. Mutations in telomerase and shelterin c
DNA damage, a processwhich is exacerbated by environmental stresses. This leads to prematu
reserve or results in haematological or non-haematological cancers.explained by other means. Evidence from the POT1b−/− model of DC
shows similar patterns of melanin distribution to those caused by
ultraviolet light exposure in human skin, which is itself a DNA damage
response. This might suggest that the abnormal skin pigmentation
seen in DC is a response to DNA damage [62]. The parallels between
the abnormal skin pigmentation in DC and increased susceptibility to
DNA damage in Dkc1 mutant mouse epithelial cells with the type of
skin pigmentation seen as a response to UV damage are intriguing and
suggest a mechanism for some of the non-haematological features
that does not simply rely on premature cell death.
However, exhaustion of the local stem cell pool in any affected
organ is usually considered to be the most likely cause of disease
features in DC. Unusually rapid turnover of cells in the lungs and
gastrointestinal lining could be the driving force behind the
propensity for ﬁbrosis and tumours seen in these tissues. This
would be expected to set up a positive feedback loop, with premature
and thus excessive loss of adult cells driving excessive replication and
differentiation in the stem cell compartment. Mutations in TERT and
TERC have been directly associated with IPF [12,25,87,88] where the
telomeres are short and tissue damage is focal and scattered across the
parenchyma. It is therefore possible that a telomerase defect might be
resulting in a failure to respond to tissue damage due to the loss of
lung stem cells. IPF patients have shown some response to antioxidant
treatment including increased epithelial lung ﬂuid glutathione levels
and mildly improved lung function tests [89–92], suggesting that
prevention of cell damage or loss due to oxidative stress can improve
the prognosis. While the same effects have not yet been examined
speciﬁcally in DC-related pulmonary disease, it is reasonable to
suppose that there are parallels in the pathogenesis in terms of
excessive cell loss.
As yet, studies of the molecular basis of non-haematological
aspects of DC are somewhat lacking by comparison to haematological
studies. Further research into the areas of, for example, organ-speciﬁc
dysfunction and solid tumour development are required in order to
better understand the down-stream effects of telomere dysfunctionomponents cause excessive telomere attrition and may increase the response to normal
re cell death and chromosome instability which eventually either exhausts the stem cell
377M. Kirwan, I. Dokal / Biochimica et Biophysica Acta 1792 (2009) 371–379on other systems and ultimately to develop a treatment to cure or
ameliorate the symptoms.
4. Summary and future directions
From a basic scientiﬁc standpoint, dyskeratosis congenita can be
considered a direct demonstration of the effect of dysfunctional
telomere biology in humans — something that has been difﬁcult to
reproduce even in common animal models such as the mouse. In this
sense it provides an excellent system for studying the complexities
and functional consequences of telomere biology. Although a general
model can be elucidated (Fig. 5) the broad phenotypic range,
involvement of multiple genetic components and the interplay
between molecular and environmental effects show that DC is a
complex disorder that has yet to be fully understood andwill no doubt
provide further insight into both telomere biology and the complex-
ities of human disease.
Even after many years of study and having uncovered the causative
genes involved, there is still no satisfactory treatment for the disease.
Further molecular studies are necessary to identify which genes are
implicated in the remaining uncharacterised cases and more research
is required to pin down the precise mechanisms involved in the
pathogenesis of DC, especially the differences between genetic
subtypes, in order for a more rational and efﬁcacious approach to
treatment to be developed. To date, the advances in the genetics of DC
have led to early diagnosis (including antenatal diagnosis) and more
rational use of drugs for the bonemarrow failure; this includes the use
of upfront oxymetholone rather than immunosuppressive therapy in
patients presenting with “cryptic” DC. They have also reinforced the
idea that in patients who are to undergo haematopoietic transplanta-
tion, drugs such as busulphan and radiotherapy should be avoided
because of the abnormal tissue repair as a consequence of the
telomere defect. Equally they have also led to a better understanding
of some related diseases such as idiopathic pulmonary ﬁbrosis and
idiopathic aplastic anaemia.
Being such a rare disease it is unlikely that pharmaceutical
companies would be willing to invest the vast sums necessary to
develop a new drug purely for this one application. Since DC is a
genetic disorder (and in the characterised cases, monogenic) it might
therefore lend itself to genetic therapy. While this has been touted for
some years, surprisingly little progress has been made in this area and
the absence of a satisfactory animal model is a signiﬁcant obstacle to
the development of a therapeutic vector.
However, because of the greater understanding now achieved with
regards to the molecular basis of DC, the ever-widening phenotype
associated with telomerase dysfunction and the involvement of
telomeres in several other disorders such as cancer and aging, DC is
being studied ever more broadly and intensively and this can only be
beneﬁcial to the wider scientiﬁc community and those unfortunate
enough to suffer from this rare disorder.
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